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A PARADIGM SHIFT IN THE DIAGNOSIS AND TREATMENT OF POLYCYSTIC
OVARIAN SYNDROME: A PRACTICE CHANGE IN PRIMARY CARE

An Abstract of the Scholarly Project by
Patricia Lynn Sullivan
The purpose of this DNP Scholarly Project was to determine whether participants’
knowledge of the updated guidelines on the diagnosis and treatment of the obese patient
with polycystic ovarian syndrome (PCOS) is increased following a continuing education
presentation. The increase in the knowledge of PCOS guidelines for an obese patient is
documented using a pretest/ posttest method following the continuing education program
which utilizes a PowerPoint presentation. Polycystic ovarian syndrome (PCOS) is the
most common endocrine disorder in women. This Doctor of Nursing Practice (DNP)
capstone project was designed to provide a literature review and best practice guidelines
delivered through the use of an educational PowerPoint presentation for the purpose of
educating nurse practitioners and nurse practitioner students on the inflammatory
complexity of a PCOS diagnosis. A portion of the presentation discussed the role of FDA
approved liraglutide in the treatment of obese women with a co-morbidity of PCOS. A
quasi-experimental one-group pretest/posttest design instrument in the form of an index
was created for this study. The index included four dimensions with four questions each.
The dimensions involved the four research questions for this project. The sample of
convenience included 16 nurse practitioners and 2 nurse practitioner students. The results
did provide data that a learning curve exists by analyzing the pretest and posttest scores
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for the PowerPoint presentation. This study did reflect the need for increased education
in nurse practitioners to more appropriately diagnose and treat the obese PCOS patient.
Keywords: PCOS, GLP I, Insulin Resistance, PCOS and Obesity, TNF-α
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CHAPTER I

INTRODUCTION
“For us who nurse, our nursing is a thing which, unless we are making
progress in nursing every year, every month, every week,
take my word for it, we are going back”,
Florence Nightingale, 1872.

Introduction
Polycystic Ovarian Syndrome (PCOS) is the most common endocrine disease
affecting women of childbearing age (Roe & Dokras, 2011). The Department of Health
and Human Services (DHHS) reports there are more than 5 million women suffering
from Polycystic Ovarian Syndrome currently (2014). According to a recent study
published in the Endocrine Society’s March 2015 issue of Journal of Clinical
Endocrinology & Metabolism, women diagnosed with PCOS are twice as likely to be
hospitalized for heart disease, diabetes, mental-health conditions, reproductive disorders’,
and cancer of the uterine lining due to an underlying inflammatory etiology. The cost of
evaluating and providing care to women with PCOS is approximately $4.36 billion per
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year (Hart & Dorghty, 2015). Similar inflammatory correlations have been identified in
obesity and PCOS (Gonzalez, Sia, Shepard, Rote, & Minium, 2014).
The National Center for Health Statistics reported in 2013 that an approximate 68
percent of Americans over the age of 18 are overweight or obese. In the past, obesity
was merely looked upon as a caloric matter versus hormonal and inflammatory causes
(NCHS, 2013). In 2013, the American Medical Association (AMA) addressed this
symptom of obesity and finally categorized it for the first time as a chronic disease state
involving gut hormone inflammatory dysregulation rather than a mere symptom (AMA,
2013).
Treatment options for obesity in the PCOS patient are limited. These limitations
include the complexity of the disorder, an unknown etiology, and lack of financial
backing for research (NIH, 2012). Both metabolic and reproductive abnormalities are
amplified in PCOS similar to the obese patient (Franks, 2011). In turn, obesity in the
PCOS patient exacerbates objective and subjective findings due to an increase in insulin
resistance, androgens, and inflammatory markers. These findings are already elevated at
baseline in PCOS, independent of a co-morbidity of obesity (Gonzalez, 2015). Adipose
tissue becomes a catalyst to PCOS (2015).
Genetic and epigenetic influences are linked to PCOS (Gonzalez, 2015). It is likely
that epigenetics is more of a facilitator to the disease rather than solely from genetic
inheritance (Franks et al., 1997). In the research, evidence based findings report dietary
habits such as increase glucose adds to the epigenetic expressions. Recent findings in the
study of PCOS report that metabolic deviations and ovarian dysregulation are caused by
2

insulin resistance and inflammation (Gonzalez, 2015). This is the linkage which
associates the obese patient without PCOS and the effects of an increase in adipose tissue
enhancing insulin resistance and inflammation.
Identifying and treating PCOS is ambiguous among many health care
professionals (NIH, 2012). This is due to the similarities of objective and subjective
findings in other endocrine disorders (Boyle & Teede, 2011). Current PCOS guidelines
recommend lifestyle changes in caloric intake and exercise for weight loss. No
medication recommendation is offered (Endocrine Society, 2013). Research finds
lifestyle modifications have limited outcomes in PCOS with weight loss (2013). New
obesity guidelines offer a novel treatment for weight loss in PCOS which also impedes
inflammatory markers. These inflammatory markers are key in exacerbation of the
disease process (AACE/ACE, 2016). This therapy contradicts the previous guidelines
from the Endocrine Society on weight loss in the PCOS patient.
In December 2012, a PCOS workshop was sponsored by the Office of Disease
Prevention and the Eunice Kennedy Shriver National Institute of Child Health and
Human Development through the NIH. Invited experts came together to discuss
independent and unbiased evidence to facilitate discussion. An executive summary
indicated for most of the twentieth century PCOS has been a poorly understood
condition. Also, the distractive title limited the assumptions of the disease to an isolated
gynecological state. It also allowed for an underdevelopment in education for clinicians
and need for funded research in discovery of the metabolic causes and pathologies of the
disease state (NIH, 2012).
3

In a final position paper written by the NIH selected committee, they
recommended a change in the name of the disorder. The name change would further
reflect the complex inflammatory, metabolic, hypothalamic, pituitary, ovarian and
adrenal interactions which characterize this disease state. The experts also recommended
future translational research on mechanisms which alter the hormone functions. This
would allow for the establishment of models to be developed in identifying innovative
therapies for the treatment of PCOS due to the underlying inflammatory and metabolic
components with PCOS (NIH, 2012).
At the American Diabetes Association Scientific Conference June, 2016, an
Australian Endocrinologist presented a lecture entitled, “Clinical Update and
Implications – Renaming PCOS.” The changed name to be considered is “Metabolic
Reproductive Syndrome” (Teede, 2016).
The purpose of this research is to disseminate updated knowledge and correlations
between inflammatory and metabolic dysregulation research findings with PCOS. The
more interesting aspect is to strongly support a paradigm shift in treatment of the obese
patient with a co-morbidity of PCOS. Documented antiquated guidelines are causing
missed diagnosis and sub-therapeutic treatment options for this misunderstood population
(NIH, 2012). In turn, research allows for opportunities to increase future funded research
for metabolic treatments despite the BMI. This syndrome deserves further exploration in
order to find a cause.
Description of the Need for Clinical Practice Guidelines
In 2013, The Endocrine Society appointed a Task Force of experts to formulate
4

practice guidelines for the diagnosis and treatment of PCOS. The Clinical Guide
Subcommittee deemed the diagnosis and treatment of PCOS a priority area in need of
practice guidelines (p. 4570). Primary and secondary causes along with correct diagnosis
is imperative for treatment options (Jensterle, Kocjan, Pfeifer, Kravos, & Janez, 2010;
NIH, 2012). Implementing this guideline of recommendations assists in an appropriate
diagnosis consistent with evidence in order to treat appropriately each patient based on
the diagnosis and co-morbidities. These guidelines are aimed at helping physicians and
patients understand a complex condition which often has diverse symptoms (2013).
Inflammation is hallmark in the pathophysiology of PCOS (Gonzalez, 2011). The
effect of inflammatory markers like Tumor Necrosis Factor-alpha (TNF-α), among others
are responsible for these symptoms and co-morbidities. Similarities of increased
inflammatory markers are seen between obesity alone and the obese, PCOS patients
(Gonzalez, Sia, Shepard, Rote, & Minium, 2014). A further discovery from the research
is an elevation in these inflammatory markers being responsible in part for the decreased
expression of a gut hormone, GLP-1, from the L cells in the small intestine. Decreased
GLP-1 is associated with insulin resistance which further increases adipose production
(Gonzalez, 2013). For us who nurse, our nursing is a thing which, unless we are making
progress every year, every month, every week, take my word for it, we are going back
(Nightingale, 1872)
GLP-1 agonists, like liraglutide, are a class of medications that allow for insulinglucose homeostasis by promoting insulin secretion and limiting glycogen release
(Franks, 2011). GLP-1 levels in PCOS patients were found to be significantly lower
5

when compared to healthy women (Wang, Liu, Chen, Li & Qu, 2015). GLP-1
medications are often misrepresented as an insulin sensitizer because of the improved
glucose and loss of adipose tissue results with the medication. This medication has been
proven to assist in weight loss for patients with Type II Diabetes (T2DM) (Franks, 2011).
Early GLP-1 therapy may preserve pancreatic beta cell function in subjects with Impaired
Glucose Tolerance (IGT) and PCOS by reducing TNF-α. GLP-1 agonists have been
FDA approved for obesity (Whitten, 2016). This allows for the FDA approval to
prescribe liraglutide for obesity despite other co-morbidities (AACE/ACE, 2016).
The purpose of this research includes delineation of the inflammatory
pathophysiology of obesity and similarities to the obese PCOS patient. This links these
correlations with a treatment option through these guidelines. This therapeutic option
improves many outcomes of the disease. These outcomes involve an ability to decrease
key inflammatory markers and weight in these women in order to improve hormone
levels which complicate the symptoms of PCOS.
Significance to Nursing and the Role of the Family Nurse Practitioner
Nursing as a profession continues to evolve from its inception. Florence
Nightingale was the change agent of her time, moving the nursing concept from a
vocation to a profession (Ulrich, 1992). A famous quote from her is, “Unless we are
making progress in nursing every year, every month, every week, take my word for it, we
are going back” (Ulrich, 1992). Discussions across the United States in Doctoral nursing
programs are focused on the current paradigm shift this profession is facing in the fluidity
of current healthcare challenges (Sullivan, 2013). The need for clinical based nursing as
6

clinicians, researchers, and scientists is at the forefront as the DNP gains leadership in the
healthcare community (2013). The significance to nursing parallels Florence Nightingale
on the challenge to evolve.
A paradigm shift in 2013 classifying obesity as a disease rather a than symptom
allows nursing the ability to treat obese patients the same as treating hypertension,
diabetes, and all other disease states (AMA, 2013). This permits a new level of care and
therapeutic treatment options gradually being covered by insurance companies for the
overweight and obese patient population. Along with obesity, treatment guidelines
established for PCOS potentially expedites the diagnosis and treatment to allow for a
decrease in potential chronic co-morbidities that are associated with PCOS (NIH, 2012 )
Specific Aims/Purpose
This research accomplishes the following DNP essentials in disseminating the
paradigm shift in the diagnosis and treatment of PCOS by: 1) completing an exhaustive
literature review integrating the link between liraglutide, inflammatory marker
similarities in obesity and PCOS, improvement of hormone levels, and weight reduction
as treatment for obese patients with PCOS; 2) Developing an educational PowerPoint
with one CE credit hour through American Academy of Nurse Practitioners (AANP)
regarding obese patients with PCOS for providers. Along with this, updated practice
guidelines for the diagnosis and treatment of PCOS; 3) conducting a pretest and posttest
for the continuing education program; and 4) summarize the impact of the project on
practice and recommendations for future opportunities.
Theoretical Framework
7

Albert Einstein was quoted
“… creating a new theory is not like destroying an old barn and erecting a
skyscraper in its place. It is rather like climbing a mountain, gaining new
and wider views, discovering un-expected connections between our
starting point and its rich environment. But the point from which we
started out still exists and can be seen, although it appears smaller and
forms a tiny part of our broad view gained by the mastery of the obstacles
on our adventurous way up” (Einstein, 1938).
Chaos Theory
Conceptual shifts are occurring in many areas of healthcare and medicine based on
the premises of the chaos theory (Hoffman, 2000). Complexity science utilizes the Chaos
theory to expand on knowledge rather than discovering new knowledge (2000).
The chaos theory summarizes the undertones of order in a state of total
disorganization hammering the healthcare system in the United States currently. Chaos
Theory frames the understanding with nursing in being willing to adjust and being
malleable in this current paradigm shift with medicine (Grossman & Valiga 2013). Clark
(2008) states in her book, Classroom Skills for Nurse Educators, the application of the
chaos theory for nurse educators helps students during simulations that allows for a
purpose of uncertainty. This theory helps students understand the uncertainty of a new
patient. At that juncture varied appropriate interventions can be identified and adjusted
as the simulated patient changes (2008).
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This is similar to the uncertainty of a patient with PCOS. Diverse epigenetic
challenges arise with multiple variables altering the patient’s symptoms and treatments at
any given time (Gonzalez, 2015). Epigenetic variables include the patient’s diet, lifestyle,
and environment among other gene altering stimuli (2015). Treatment algorithms and
protocols are limited and guideline attempt to force all patients with PCOS into “boxes”
that may not be appropriate with each unique presentation (NIH, 2012).
Grossman and Valiga (2013) incorporates a discussion allowing the chaos theory to
be applied to patient-centeredness, critical thinking, and creativity during this time for
improved patient outcomes (2013). The conceptual terms consistent within this
theoretical framework allow for a comparison applicable to this research. Definitions of
concepts in relation to the chaos theory are in the following table. A second table
following defines the parallel of these definitions to PCOS.
Table 1. Chaos Theory Conceptual Definitions (Oestreicher, 2007)
Causality Principle
Characteristic Lyapynov
time
Feedback

Determinism
Predictability

Model

Dynamical system

Every effect has an antecedent proximate cause.
The characteristic time of a system is defined as the delay
when changes from the initial point are multiplied by 10 in
a phase space
A response to information, that either increases effects
(positive) or decreases them (negative), or induces a cyclic
phenomenon
A philosophical proposition that every event is physically
determined by an unbroken chain of prior occurrences
This refers to the degree that a correct forecast of a
system’s state can be made either qualitatively or
quantitatively.
A patter, plan, representation, or description designed to
show the structure or workings of an object, system, or
concept.
A system that changes over time in both a causal and a
deterministic manner; i.e, its future depends only on
9

Phase space

Integral System

Linear System
Attractor
Sensitivity to initial
conditions.

phenomena from its past and its present and each given
initial condition will lead to only one given later state of the
System (determinism). Systems that are noisy or stochastic,
in the sense of showing randomness, are not dynamical
Systems, and the probability theory is the one to apply to
their analysis.
An abstract space in which all possible states of a System
are represented, which, each possible state of the System
corresponding to one unique point in the phase space.
In mathematics, this refers to a System of differential
equations for which solutions can be found. In mechanics,
this refers to a system that is quasiperiodic.
A system is said to be linear when the whole is exactly
equal to the sum of components.
A set to which a dynamical System evolves after a long
enough time.
This is when a change in one variable has the consequence
of an exponential change in the System.

In reviewing the conceptual terms describing the chaos theory, this research
identifies a parallel description of the terms as themes. These themes resonate through the
PCOS disease state and symptomology of the females with this disorder. The purpose of
this research is to focus on the obese PCOS patient and inflammatory marker elevations.
These elevations could potentially have devastating outcomes if not harnessed. The
diversity of the symptoms and treatments depend on genetic and epigenetic factors
influencing a multitude of cause and affect exchanges with each patient (Gonzalez,
2015). In the following diagram correlations are identified with the conceptual definitions
paralleling this research.
Definition of Terms:
This section describes the definitions for the terms utilized in this study:
Polycystic Ovarian Syndrome – A condition in some women of abnormal hormone levels
10

Table 2. PCOS Conceptual Definitions in Relation to the Chaos Theory
Causality Principle
Characteristic Lyapynov
time
Feedback

Determinism
Predictability
Model
Dynamical system
Phase space

Integral System

Linear System
Attractor
Sensitivity to initial
conditions.

Elevated inflammatory markers, GLP-1 and adiponectin
abnormality, insulin resistance.
The time a patient with PCOS increases adipose tissue
causing worsening of symptoms from the initial symptoms.
Increased Inflammatory markers, worsening insulin
resistance, elevated androgens, obesity, infertility, acne,
excessive body hair, male pattern hair loss, diabetes, etc.
Polycystic Ovarian Syndrome
Hypothesis of elevation of adipose tissue and the symptoms
of PCOS in obese females.
Adipose tissue
Hormonal changes that are consistent with the probability
of a diagnosis of PCOS
An abstract space in which all possible presentation of an
obese patient with PCOS is represented which, each
possible presentation of the symptoms correspond to one
unique point in the parameters of this space.
Domino effect of dysregulation of female hormones
secondary to inflammatory markers from an increase in
adipose tissue.
The perfect hormone regulation that does not deviate from
normal
Elevated inflammatory markers, Insulin resistance,
Amenorrhea, Ovarian Follicles.
Elevated inflammatory markers, Insulin resistance,
Polycystic Ovarian Syndrome, hypertension, diabetes,
vasculopathies, infertility.

resulting in irregular menstruation, hirsutism, acne, ovarian cyst, and infertility.
Treatment involves weight loss and hormones (Sell, Rothenburg, & Chapman, 2012)
Liraglutide is marketed under the trademark Victoza© and Saxenda© (Whitten, 2016).
TNF-α – is directly proportional to fat mass and has been shown to be involved in the
development of insulin resistance. It decreases insulin receptors and down-regulates
several steps in the insulin-signaling pathway. It is a protein which is produced chiefly
by monocytes and macrophages in response to endotoxins that mediate inflammation. It
11

is an inhibitor of insulin on the insulin receptor increasing insulin resistance. This is
elevated in PCOS and worsens insulin resistance, GLP-1 resistance, and GLP-1
production (Gagnon et. al., 2015)
Insulin resistance – A reduction to the sensitivity of insulin by the body’s insulindependent processes such as glucose uptake and lipolysis (Franks, 2011).
Epigenetics - Epigenetics describe the alterations of gene expression despite any
alterations to the genetic sequence (Chuang & Jones, 2007)
GLP-1 – one of two intestinal hormones secreted when nutrients such as carbohydrates
and lipids are present in the small intestine. It stimulates the release of insulin from
pancreatic beta cells in conjunction with carbohydrates that are absorbed from the gut
while inhibiting glucagon secretion, stomach emptying and food intake. It regulates
postprandial glucose homeostasis. PCOS hormone dysregulation involves a decreased
production and sensitivity of GLP-1 which leads to worsening symptoms of the disease.
Body mass index (BMI) – A useful tool to calculate body fat. It is a measurement of
weight (kilograms) divided by the height (meters) (Institute for Clinical Systems
Improvement, 2013). It is useful to correlate with coexisting health problems (2013).
Clinical Practice Guidelines – Reports which include recommendations for improving
patient care and outcomes through disseminating a systematic review of evidence and an
association of the benefits and harms of treatment options (National Guideline
Clearinghouse, 2011).

Chapter Summary
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PCOS is the number one endocrine disorder in women. Coupled with obesity,
inflammation worsens the disease process. Many studies have looked at the long term
effects of the obese PCOS patient. New guidelines were implemented in May, 2016 for
obesity associated with PCOS and in 2013 for PCOS. Nurse practitioners in the primary
care setting must be educated on to appropriate diagnosis and treatment of PCOS.
Chapter II presents a literature review on the updated guidelines as well as multiple
research studies utilizing medication to treat the obese PCOS patient. It goes on to
highlight key guidelines that are FDA approved in treating PCOS.

13

CHAPTER II

REVIEW OF THE LITERATURE

Introduction
This chapter discusses research and guidelines on the diagnosis and management
of PCOS with a focus on the obese PCOS patient. The purpose of this research is to
disseminate imperative knowledge to support a paradigm shift in the diagnosis and
treatment of PCOS with obesity. This is achieved by blending current evidence based
guidelines for PCOS and Obesity along with supportive research studies reinforcing
novel trends in pathophysiology and treatment.
The review of literature is achieved through multiple online databases. The
research is generally limited to the last five years. Due to the diagnosis classification
being a rare disease, some research exceeds the five year mark to allow the reader full
bodied research from the inception of the diagnosis.
The phrases being used for search includes “PCOS,” “obesity,” “GLP-1 agonists
and obesity,” “Clinical practice guidelines in PCOS” and “inflammatory markers with
PCOS”. The statistical information from the website of the Centers for Disease Control
and Prevention and the National Institutes of Health are reviewed. In searching these
different words and phrases, there are over 30 peer-reviewed articles with information
14

being utilized for this scholarly project. The following categories distinctly satisfy a
portion of necessary essentials for the DNP program. The first category is a literature
review correlating obesity, PCOS, inflammatory markers, and lirglutide. The second
category involves developing a one hour CE, through AANP, Power Point presentation.
A pretest and posttest comparison involving area nurse practitioners and nurse
practitioner students is conducted. The CE includes the pathophysiology, diagnosis, and
treatment of obesity in the PCOS patient. The third category is further dissemination of
the information from this research in future state and national conferences. This allows
for updated practice changes in the primary care setting to be the rule and not the
exception in treating PCOS.
Practice Change Guidelines
The Endocrine Society 2013 guidelines, Diagnosis and Treatment of Polycystic
Ovarian Syndrome: An Endocrine Society Clinical Practice Guideline,” recommends
three primary recommendations which delineate into 32 more precise recommendations
for the diagnosis, co-morbidities, and treatment of PCOS. The Endocrine Society
appoints a Task Force of experts to formulate practice guidelines for the diagnosis and
treatment of PCOS. The Clinical Guide Subcommittee deems the diagnosis and
treatment of PCOS a priority area in need of practice guidelines (p. 4570). Primary and
secondary causes along with correct diagnosis is imperative for the correct treatment of
PCOS (Jensterle, Kocjan, Pfeifer, Kravos, & Janez, 2010).
Implementing this guideline and bundle of recommendations is to individually
diagnose appropriately each patient according to the severity of the disease and co15

morbidities. These guidelines are aimed at helping physicians and patients understand a
complex condition that often has diverse symptoms (2013). PCOS continues to be
underdiagnosed in adolescents and adults due to the complexity and diverse subjective
and objective findings (March et. Al., 2012).
Under diagnosis of PCOS is concerning due to the long term reproductive health
consequences and associated cardio metabolic risks. These women have increased risk of
metabolic syndrome, diabetes, heart disease, and death (Coviello, Legro & Dunaif, 2006).
Due to this, assessing and establishing the diagnosis is important for further counseling
and treatment.
Three evidenced based diagnostic criteria protocols have been available but tend
to be under-utilized by healthcare providers and medical professions currently. This is
due to variations and confusion among the different specialties involved in treating PCOS
(Bonny et. Al., 2012). These protocols include the NIH 1990, Rotterdam 2003, and
Androgen and Endocrine (AE)-PCOS Society 2006. The following tables will identify
key criteria for each protocol.
Table 3. Guidelines for the Diagnosis of PCOS
NIH 1990

Rotterdam 2003

AE-PCOS Society 2006

Chronic anovulation

Oligo-and/or anovulation

Clinical and/or biochemical

Clinical and/or biochemical

Clinical and/or biochemical

signs of Hyperandrogenism

signs of Hyperandrogenism

signs of Hyperandrogenism

Ovarian dysfunction (Oligo-

(with exclusion of other

Polycystic ovaries

anovulation and/or

etiologies, e.g., congenital

(Two of three criteria

polycystic ovarian

16

adrenal hyperplasia)

needed)

morphology)

(Both criteria)

(Both criteria needed)

Practice Change Recommendations for Implementation
The Endocrine Society published updated recommendations for PCOS in 2013.
Obesity is addressed. Treatment options for the obese PCOS patient in the guidelines.
These guidelines are limited and state that benefits to the patients are uncertain in
improving PCOS symptoms (Endocrine Society, 2013). Research clearly identifies that
weight loss decreases inflammatory markers in patients with PCOS (Gonzales, 2015).
In 2016, the American Association of Clinical Endocrinologists (AACE) and American
College of Endocrinology (ACE) introduced updated clinical practice guidelines for
comprehensive medical care of patients with obesity. PCOS is listed as a co-morbidity of
obesity and offers liraglutide as a treatment option for PCOS (AACE, 2016). The
Endocrine Society in 2013 offered no medication as a treatment for obesity in the PCOS
patient (2013).
Diagnosing and Treating PCOS, the Endocrine Society recommendations contain
three primary recommendations with a total of 32 separate detailed recommendations
divided within the three primary guidelines. The delineation of these being outlined (See
Table 4). The highlighted guidelines are the focus of this research.
Table 4. Endocrine Society Practice Change Guidelines
1.0 Diagnosis of PCOS

1.1 Diagnosis Criteria
1.2 Diagnosis Criteria for adolescents
1.3 Diagnosis Criteria for perimenopause
or menopause with presumptive
symptoms
17

2.0 Associated morbidity and evaluation

2.1 Documented cutaneous manifestations
2.2 Screening ovulatory status
2.3 Exclusion of other causes of if
infertility
2.4 Preconception assessment of BMI,
B.P., and OGTT
2.5 No intervention for prevention of
PCOS in offspring
2.6 Against routine ultrasound screening
for endothelial strip
2.7 Screening PCOS females for
adiposity by BMI and waist
circumference
2.8 Screening for Depression
2.9 Screen for Obstructive Sleep Apnea
2.10 Awareness of Fatty Liver Disease,
but no screening
2.11 Recommend OGTT to screen for
glucose intolerance and type II diabetes
2.12 Screening for CVD

3.0 Treatment

3.1 Oral Contraceptives as first-line
management of PCOS symptoms
3.2 Screening for contraindications of
Oral Contraceptives
3.3 Exercise management in the
treatment of obesity in PCOS
3.4 Suggest calorie-restricted diets for
weight loss in PCOS
3.5 Suggest against first line therapy for
treatment of cutaneous manifestations of
PCOS
3.6 Recommend metformin in women
who fail first line therapy for T2DM or
IGT
3.7 Recommend clomiphene citrate as
first-line for infertility
18

3.8 Metformin suggested as an adjuvant
therapy for infertility to prevent ovarian
hyper stimulation syndrome in women
with PCOS undergoing IVF
3.9 Recommend against use of insulin
sensitizer such as inositol’s or
thiazolidineses for treatment of PCOS
3.10 Recommend against using statins for
treatment of hyperandrogenism and
anovulation in PCOS
3.11 Suggest OCs first line treatment in
adolescents
3.12 Premenarcheal girls with advanced
pubertal development, suggest OC’s
The 2016 updated obesity guidelines from the AACE/ACE allow for a paradigm
shift in the treatment of obesity in PCOS. The guidelines specific for obesity and the comorbidity of PCOS state, “What are the weight-related complications that are either
caused or exacerbated by excess adiposity? (AACE, 2016). It lists PCOS as one of 15
co-morbidities of obesity. Each recommendation is graded according to the strength of
each recommendation. Grade A and B indicate a strong or intermediate level of scientific
substantiation. The strength of evidence is graded one through four with one being
strong and four being no clinical evidence (2016).
Table 5. 2016 AACE Clinical Guidelines for Obesity with Co-Morbidity of PCOS
(AACE/ACE, 2016)
Screening for Co-morbidity of Obesity

Treatment: Is weight loss effective to treat

Premenopausal female patients with
overweight or obesity and/or metabolic
syndrome should be screened for polycystic
ovary syndrome by history and physical
examination; all patients with PCOS should
be evaluated for the presence of overweight
or obesity. (Grade B; BEL 2)
R48. Women with overweight or obesity
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PCOS? How much weight loss would be
required?

and PCOS should be treated with lifestyle
therapy with the goal of achieving five
percent to 15 percent weigh loss or more to
improve hyperandrogenism,
oligomenorrhea, anovulation, insulin
resistance, and hyperlipidemia; clinical
efficacy can vary among individual patients
(Grade A; BEL 1)
R49. Patients with overweight or obesity
and PCOS should be considered for
treatment with orlistat, metformin, or
liraglutide, alone or in combination, since
these medications can be effective in
decreasing weight or improving PCOS
manifestations including insulin resistance,
glucose tolerance, dyslipidemia,
hyperandrogenemia, oligomennorrhea, and
anovulation (Grade A; BEL 1).
R50. Selected patients with obesity and
PCOS should e considered for laparoscopic
Roux-en-Y gastric bypass to improve
symptomatology including restoration of
menses and ovulation (Grade B; BEL 2)

Treatment Goals for overweight or obese
patients with PCOS with BMI> 24:

Decrease of weight by 5-15 percent
Ovulation
Regularization of menses
Reduced hirsuitism
Enhanced insulin sensitivity
Reduced serum androgen levels

Implementation Plan
In an attempt to understanding the disease process of PCOS with obesity, it is
difficult to have a one size fits all treatment algorithm. In saying that, a basic evidenced
template allows for consistency to distinguish a depth of credibility for the diagnosis and
treatment of PCOS. Initiating new guidelines in a primary care practice can be difficult
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due to the complexity and multiple symptoms of PCOS. Utilizing an implementation
guideline could facilitate an easier transition in the practice change for PCOS.
The Registered Nurses’ Association of Ontario (RNAO) environmental scan from
the Toolkit: Implementation of Clinical Practice Guidelines (2013) assesses the potential
readiness of a primary care practice to implement change in PCOS guidelines. Results of
the findings are located in Table six that discusses barriers and facilitators.
Table 6. Primary Care Practice Readiness to Change in the Treatment of PCOS
Element

Question

Facilitators

Structure

To what extent does
decision-making
occur in a
decentralized
manner? Is there
enough staff to
support the change
process?

Recognition of
collaborating
physician and midlevel in need of
specific guidelines
for PCOS patients

Various protocols
from different
specialties for
PCOS, some
contradicting

Workplace Culture

To what extent is
the CPG consistent
with the values,
attitudes and beliefs
of the practice
environment? To
what degree does
the culture support
change and value
evidence?

The reputation and
specialty of the
providers in each
practice.

Inconsistent
protocols used due
to types of patients,
insurance, family
support, etc.

Communication

Are there adequate
(formal and
informal)
communication
systems to support
information
exchange relative to
the CPG and the
CPG

Communication
involves the midlevel and physician
along with
educating patients

Not educated on
PCOS. “Not
knowing what you
don’t know”
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Barriers

implementation
process?
Leadership

To what extent do
the leaders within
the practice
environment support
(both visibly and
behind the scenes)
the implementation
of the CPG?

The support of the
staff and other
providers in the
office.

Decrease level of
education and closemindedness towards
the disease.

Knowledge skills
and attitudes of
target
group(Includes
Nursing Leadership,
Staff Nurses and
Nurse Educators)

Does the staff have
the necessary
knowledge and
skills? Which
potential target
group is open to
change and new
ideas? To what
extent are they
motivated to
implement the
CPG?

The continued
education
undergone by the
physicians and midlevels the
experience with
PCOS and ability
to utilize the
guidelines
appropriately

Lack of interest or
education to provide
appropriate care

Commitment to
quality management

Do quality
improvement
processes and
systems exist to
measure results of
implementation

Quality
improvement has
being a part of
office infrastructure

Lack of resources on
PCOS and Obesity
and need for quality
management

Availability of
resources

Are the necessary
human, physical and
financial resources
available to support
implementation?

Resources are
readily available
with involvement of
the diagnosis and
treatment of PCOS

Unclear of updated
guidelines for
obesity and PCOS

Interdisciplinary
relationships

Are there positive
relationships and
trust between the
disciplines that will
be involved or
affected by the
CPG?

Support and use of
these guidelines will
allow for other
disciplines to be
educated on this
disease

Misunderstanding of
the disease process
across different
specialties causes
mixed focus of the
diagnosis and
treatment of PCOS
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Patients

Are patients happy
with results of new
guidelines

Results of patient
evaluations

Lack of desire for
the patients to fill
out evaluations

According to the Endocrine Society, treatment of obesity in the PCOS patient is
not associated with improvement in symptoms (Endocrine Society, 2013). The purpose of
this literature review is to present research to substantiate the importance of weight loss
in PCOS in the reduction of symptoms. It then continues to discuss improvement in comorbidities with the introduction of liraglutide as a treatment. Weight loss as well as the
use of liraglutide decrease inflammatory markers, especially TNF-a, which are key in the
pathophysiology of PCOS (Gonzalez, 2015; Gagnon et. al, 2015).
Tumor Necrosis Factor-alpha
Tumor Necrosis Factor-alpha (TNF-α) is a pro-inflammation cytokine which
encourages a wide range of reproduction related disorders (Gagnon et. al., 2015).
Genetic and epigenetic expressions of this inflammatory marker lead to excess
production of TNF-α. Because of excessive TNF-α, elevated production of other
androgens in the system produce the classical symptoms of PCOS (Fauser et. Al, 2012).
These androgens include testosterone, DHEA-S, insulin among others.
While obesity is well known to create a pro-inflammatory state, with increased
levels of TNF-α, recent literature suggests PCOS patients exhibit increased levels of these
inflammatory markers independent of obesity (Gonzalez, 2015). Inflammatory markers
also secrete abnormally in response to dietary components, such as glucose. This
promotes a greater pro-inflammatory and oxidative state, which is elevated when obesity
is present (Gonzalez, Sia, Shepard, Rote & Minium,2014).
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Genetic and Epigenetic Polymorphisms of TNF-α in PCOS patients have been
confirmed versus control groups in recent studies (Gan & Nalliah, 2015). Hector et. Al
(2001) demonstrates high serum levels of TNF-α in PCOS patients. TNF-a biomarkers
have been identified as a screening for potential candidates and their risk for developing
PCOS (2015). The following diagram is a simplified algorithm to how TNF-a causes
insulin resistance.
Elevated levels of TNF-α contribute to insulin resistance through post receptor
restraint of insulin receptors. TNF-α impedes insulin uptake leading to a decrease in
insulin sensitivity. Consequently, hyperinsulinemia occurs as a compensatory
mechanism, which in return, promotes an elevated androgen state and increase in
adiposity (Gonzalez, F., 2015).
Since the discovery of TNF-α, the understanding of the various effects on the human
body is increasing. The pathophysiology of diseases linked with this marker

Figure 1. Inflammatory Marker Effects on Insulin and the Cell (Taylor, 2016)
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involves multiple organ systems. TNF-α receptors can be located on virtually every cell
of the body. With this increase in understanding the role of TNF-α in diseases an
increase in therapeutic agents rise (LaDuca & Gaspari, 2001)
In 1999 Dr. Gonzalez states that circulating TNF-a is elevated independent of
obesity in PCOS (Gonzalez et. al., 1999). Dr. Gonzalez discusses multiple connections to
PCOS and TNF-a in his peer reviewed article, Inflammation on Polycystic Ovary
Syndrome: Underpinning of insulin resistance and ovarian dysfunction (2012). Along
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with this, research continues to have no definite etiology of PCOS. Recent literature
points toward a pattern consistent with inflammatory markers’ response to genetic
mutations and epigenetic factors which could support an etiology to this syndrome
(2012).
PCOS subjects have been shown to produce elevated levels of TNF-α in response
to glucose independent of obesity. Glucose intake along with acute hyperglycemia causes
insulin resistance. Insulin resistance becomes a potent activator of several inflammatory
cellular pathways (Khodabandehloo et al., 2015). Of significant importance,
physiological changes occur in the presence of excess insulin, resulting in a greater
luteinizing hormone (LH) response. This increase in LH function contributes to the
abnormal ovulation and increase in androgens observed in PCOS patients (Franks, 2011).
Further research involving the pathophysiology of PCOS is the elevation of TNFα from the ovaries that elevate insulin and androgen levels (Hector et. Al, 2001). Recent
genetic research is on the brink of identifying TNF-α mutations in the genetic sequences
that are unique to PCOS patients (Gan & Nalliah, 2015). Gan and Nalliah (2015) have
verified this TNF-α mutation could potentially be related to lowering GLP-1 production
and uptake in the cells initiating the PCOS disease process.
GLP-1 Agonists
The purpose of this project is focused research regarding the parallel between
obesity and the obese PCOS patient in the therapeutic benefit of liraglutide, a GLP-1
agonist. An important parallel in treating with liraglutide is a decrease in inflammatory
markers, like TNF-α, and weight. Elevated TNF-α levels lower GLP-1 production in the
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gut as well as GLP-1 uptake in the peripheral organs (Gagnon, 2015). An observational
research study concludes that GLP-1 inhibition occurs in PCOS patients independent of
BMI or oral contraceptive use during a three hour glucose tolerance test. TNF-α was not
tested in this research (Aydin, Arusoglu, Koksalt, Cinar, Aksoy & Yildiz, 2014 )
Molecular cardiologists published a study in 2013 correlating GLP-1 agonists
with a decrease in the over-expression of TNF-α in mice who were fed a high fat diet for
up to 32 weeks versus the mice control group (Noyan-Ashraf et. al., 2013). Their
conclusion supports GLP-1 in the activation of several cardio-protective pathways in
vitro (2013).
The research for GLP-1 agonist treatment of weight loss in PCOS, independent of
BMI is limited and the subject numbers are small. In the literature review, GLP-1
agonists have been extensively researched for T2DM, obesity and non- alcoholic
steatohepatitis (NASH). Other research supports GLP-1 agonists with treatment for
hypertension, metabolic therapy, Alzheimer’s disease and antipsychotic medication
induced obesity (Hoang et. al., 2015; Ishoy, Fliip, Vilsboll, Glenthoj, & Bjorn, 2013).
The following diagram in Figure two demonstrates GLP-1 and insulin on the cell
receptors.
Multiple peer-reviewed research outcomes identify similar results involving GLP-1
induced weight loss in patients who have diagnoses other than PCOS. In 2013, a
randomized controlled trial compares antidiabetic medications, including GLP-1 agonists
for treatment of T2DM (Brady, Davies, Gray, Saeed, Smith, Hanif & Khunti, 2013).
Figure 2: GLP-1 and insulin at the Cell Receptors (Taylor, 2016)
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Although weight loss is a secondary outcome liraglutide, which is a GLP-1 agonist, did
statistically find weight loss in this group (>-1kg). This was the first randomized
controlled trial comparing a sulfonurea to a GLP-1 receptor agonist in patients with
diagnosed T2DM who were fasting during Ramadan. It is a 12 week study with 70
subjects finishing the trial (2013).
The second review is a study involving long-term efficacy and safety in
comparing liraglutide, glimepiride and placebo with T2DM. It is randomized to
liraglutide, placebo, or glimepiride with all to include metformin. It is a two year
retrospective study from patients who enroll in the LEAD-2 study and continues after the
26 week trial was complete. Weight loss with liraglutide is significantly greater than
with metformin therapy (p=0.0378) (Nauck, Hermansen, Thomsen, During, Shah,
Tankova, Miltha & Matthews, 2013).
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The third review involves a 12-week prospective randomized open-label study
involving metformin or liraglutide with a primary endpoint of weight loss. The PCOS
subjects are diagnosed by Rotterdam criteria. A statistical weight loss is observed (Sever
et. al., 2015).
The fourth review involves an observational study from Denmark. The aim is to
evaluate liraglutide on weight loss with obese and overweight women with PCOS.
Treatment is significant in the overweight and obese women on liraglutide. A mean
decrease of the BMI of 3.2 kg/m2 is found (Rasmussen & Lindenberg, 2014).
The fifth review involves liraglutide and improvement of hypertension and
metabolic perturbation in a rat model of PCOS. A secondary outcome involves noted
weight loss. A significant decrease in body weight (p<0.01) is measured. Utilizing
research in a very controlled setting allows for more accurate results in the endpoints
being studied (Hoang et. al., 2015).
The sixth review is conducted as a randomized control trial to research the question
involving GLP-1 receptor agonist and maintenance of weight loss due to a decrease in
plasma leptin. This is an interesting description of leptin in the methodology and results.
The subjects are randomized, after a 12 percent weight loss into the treatment with GLP1 agonist and the control being without treatment. The study is able to conclude that
GLP-1 agonists maintain the 12 percent weight loss for one year and could prevent
prediabetes and obesity (Iepsen, Lundgren, Dirksen, Jensen, Pedersen, Hansen, Madsbab,
Holst & Torekov, 2014).
Assimilating the Research
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This researcher begins to review case studies of patients and gather evidence based
research to cultivate a trend of family history, genetics, epigenetics, medical histories,
lifestyle failures and past medical therapies corresponding with the diagnosis of obesity
and co-morbidity of PCOS. A common theme in the research involves gut hormones
and the effect of insulin resistance in these women. This research leads to the connection
of insulin resistance (IR) to GLP-1 (Drucker, 2006).
Next, this research attempts to integrate the similarities of inflammatory markers
and insulin resistance in PCOS and obesity. This integration leads to a consistent theme.
These patients with increasing inflammatory markers complicate the ability to improve
without intervention. Once the weight gain begins, increased adipose tissue complicates
the overall hormone dysregulation with the inflammatory markers produced from the
tissue. It is like a train leaving the station. Because of this hormone dysregulation, if
affected women exercise and eat minimally, the insulin resistance will not allow for
metabolism of adipose. Lifestyle changes have shown little result (Endocrine Society,
2013).
This is where GLP-1 comes into play. GLP-1 is an incretin hormone secreted in a
nutrient dependent dose. It stimulates glucose dependent insulin secretion (Drucker,
2006). GLP-1 receptors are not only located in the pancreas, but also the kidney, lung,
heart, and the peripheral and central nervous system (2006). These are all the areas
affected by obesity and PCOS as mentioned earlier in the literature review.
Both lean and obese women with PCOS show mutated alterations in the secretion
of GLP-1 both fasting and post-prandial (Aydin, Arusoglu, Koksai, Cinar, Aksoy, &
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Yidliz, 2014). Recently researchers have found a strong link with PCOS to IR, a genetic
condition often associated with diabetes (Hoffman et. al., 2016). IR is a condition in
which muscle, fat, and liver cells do not respond properly to insulin and thus cannot
easily absorb glucose from the bloodstream. This causes production of increasingly
higher levels of insulin to assist with entry of glucose into the cell. This exacerbates the
disease process causing more insulin resistance, potential weight gain, and worsening of
hormone dysregulation (Gonzalez, 2015; Gonzalez, Sia, Shepard, Rote, & Minium,
2014).
Chapter Summary
The purpose of this literature review is to educate the reader on updated research
and paradigm shifts in the diagnosis and treatment of the obese PCOS patient. The
disease process is a culmination of both genetic and epigenetic expressions of each
affected female. Treatment options have been limited as the true etiologies have not been
identified at this juncture. This research delineates the links between obesity and PCOS
in order to educate nurse practitioners on a new treatment option for PCOS.
Identification and understanding of the individualized hormone dysregulation in
PCOS is vital. One size does not fit all with this disease process. Once the diagnosis is
made, distinct treatment plans for each patient is imperative based on a very thorough
history and physical. Laboratory studies and other diagnostics should be addressed. The
necessity to align hormone regulation by lowering inflammation and restoring insulin
sensitivity is the hallmark of PCOS (Gonzalez, 2015).
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Once the initial inflammation has been addressed research is demonstrating that
obesity, infertility, glucose dysregulation, and hormone dysregulation improves. The
patient’s overall self- esteem, quality of life and overall health improve. PCOS is a very
complex disease process with divergent assumptions of causes and treatments. The
origins of PCOS must be recognized. Chapter III discusses the research methodology,
protection of human subjects, design of instruments, project procedure and outcomes.
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CHAPTER III

METHODOLOGY

Introduction
This chapter includes the research design, samples, instrument utilization, and the
analysis of the statistical outcomes. This study is designed to evaluate primary care
providers, specifically, nurse practitioners and family nurse practitioner students, in their
knowledge of the obese patient with PCOS before and after a Continuing Education (CE)
presentation on PCOS. The review of the literature discloses the updated research and
paradigm shifts in the diagnosis and treatment of the obese PCOS patient.
Research Design, Conceptualization and Measurement
The study utilizes a quasi-experimental design for measuring knowledge of the
participating learner and their understanding of PCOS based on recent guidelines for
diagnosis, assessment, and treatment of this disorder. Two practice guidelines are
bridged in order to apply up-to-date treatment in the obese, PCOS patient.
Implementation of the quantitative study allows for the review of how participating
learners are improving their education of obesity in PCOS after participating in the
presentation (Hoy & Adams, 2016). Using this style of statistical analysis allows for an
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objective approach and decreases the chance of the researcher becoming overly involved.
It also decreases potential complications early in the study (2016).
The decision to utilize a quasi-experimental design allows for testing and analysis
evaluation to identify the strength and dissemination of the education presented during
the CE. There is no control group. This study utilizes a randomized sample due to the
potential small size of the participant group. The questionnaire includes a demographic
section in order to identify the representation of the sample.
Figure 3. Project Algorithm

Research ?'s
with Webinar
approval

presentation
w/ pre-posttest ? results

Testing complete,
comparisons of results
shared

The Continuing Education program, which is presented as face-to-face presentation
with the use of PowerPoint slides, introduces an updated approach in PCOS diagnosis
and treatment in the overweight/obese population. It is anticipated that the goals of this
project will be met. It is anticipated that 100 percent of the learners will be able to
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process and synthesize the information in order to contemplate practice changes at their
place of employment.
Research Questions
The following questions are the focus of the results from the evaluation of the prepost-test and diagnosing and treating PCOS:
1. Will the Continuing Education presentation on the new PCOS Guideline increase
the knowledge base of the correlations between obesity and PCOS?
2. Will the Continuing Education presentation on the new PCOS Guideline increase
the knowledge base of diagnosing the patient with PCOS and obesity?
3. Will the Continuing Education presentation on the new PCOS Guideline increase
the knowledge base of inflammatory co-morbidities and PCOS?
4. Will the Continuing Education presentation on the new PCOS Guideline increase
the provider’s knowledge of prescribing weight loss medications for the obese
patient with PCOS?
Settings and Participants
The participants’ involvement in this research project includes attendance at the
Continuing Education presentation on the new PCOS Guideline by licensed practicing
nurse practitioners, as well as Family Nurse Practitioner (FNP) students enrolled in a
Master of Science in Nursing FNP program. These attendees are members of the
“4 State APN Group” which is a group of Nurse Practitioners in the Kansas, Missouri,
Oklahoma and Arkansas areas who meet to discuss the latest issues on a monthly basis.
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Additionally, nurse practitioner students from the same areas are invited to join this group
each month.
In order to complete and receive CE’s for the presentation, the pretest and
posttest are mandatory. The level of knowledge each participant possesses previous to
the presentation is important in order to validate the increase in knowledge base after
listening to the PCOS Guideline presentation. The participants are able to disseminate
the information and utilize it in their daily practice in order to have the confidence to
appropriately diagnose and treat the female obese patient with PCOS.
Inclusion/Exclusion Criteria
Inclusion criteria for this study involved all licensed practicing nurse
practitioners, as well as Family Nurse Practitioner (FNP) students enrolled in a Master of
Science in Nursing FNP program who attended the 4 State APN Group monthly meeting.
The monthly meeting of the 4 State APRN Group was held at The Sullivan Clinic. The
attendees completed the pretest, listened to the lecture with PowerPoint presentation and
then completed the posttest. The participants were required to be a licensed nurse
practitioner or a nurse practitioner student. No other exclusion criteria were recognized.
Protection of Human Subjects
This research capstone project falls under the status of exempt. The population of
participants included adult nurse practitioners or nurse practitioner students over the age
of 18. This study required a specific population which did not include children under 18,
prisoners, specific ethnicity groups, or specific racial populations. There is no harassment
or deception completed in order to obtain subjects for the continuing education offering.
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In order to maintain confidentiality of the test results, each participant was given a
specific code for the results. The participants are not placed at risk for a criminal or civil
liable issue in completing the webinar and test questions. The participants are not placed
at risk of damage to their reputation, finances, employment status or emotional health.
This research utilizes the criteria for the Committee for the Protection of Human
Research Subjects (CPHRS) at Pittsburg State University, Pittsburg, Kansas. The
information being obtained from the testing was utilized only for this research project.
Completed test results are stored on a HIPPA compliant computer belonging to this
researcher. Hard copies of the results will be stored in a locked filing cabinet in a locked
room in the Irene Ransom Bradley School of Nursing. All data will be kept for a
minimum of two years in a protected file then deleted from the hard drive.
Ethical and Administrative Considerations
Prior to seeking the consent of nurses agreeing to this research, authorization was
be verified by an officer of the 4 State APN Group. Written informed consents were
included prior to the first question of the demographic portion of the test. All data were
considered confidential. Prior to the beginning of the presentation, all pretests and
posttests were numbered to assure anonymity. Participants were verbally instructed they
have a right to withdraw from the research at any time.
The ethical considerations potentially placing the participants in jeopardy for this
capstone project were minimal. The design of the study was a quasi-experimental
quantitative study involving the use of a pretest/posttest method. As previously stated, the
demographics and results of the testing were handled in a confidential manner. The
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anonymity code system was stored in a different secure file on this researcher’s
computer. A roster requiring name, state of licensure and Advanced Practice Registered
Nurse (APRN) license number was utilized to confirm the validity of the participant as a
licensed nurse practitioner and to document the status of the participant as a student.
Instrument
This quasi-experimental project utilized a lecture and PowerPoint presentation
which is followed by a pretest and posttest. The instrument included an index of closeended questions for each dimension with the pretest having additional demographic and
professional practice questions not repeated on the posttest, (Appendix A). The original
instrument utilized up-to-date evidence based literature from current guidelines and a
comprehensive literature review (see Appendix A: Provider PCOS and Obesity Survey;
pretest and posttest). The test questions were based on the literature review incorporating
current practice guidelines along with research to support the inflammatory connection of
PCOS and obesity. The pretest index was comprised of four main dimensions not
including pretest professional demographic questions. These four categories were chosen
to narrow the immense research on PCOS to be more focused on the connection of
PCOS, obesity, inflammation, co-morbidities, diagnosis and treatment for weight loss in
these patients.
These four dimensions included: (a) Inflammatory connections between obesity
and PCOS; (b) diagnosis (c) inflammatory co-morbidities; and (d) medication
management in the obese, PCOS patient. The posttest index followed the same format
excluding the professional demographic questions. The style of questions included
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multiple choice, True or False, and case studies. These questions addressed the following
research questions. There were four questions per category. Each category included four
related questions. Each correct answer will be given a one. An incorrect answer will be
given a zero. Each category has a possibility of a zero to four in sum total.
Dimensions
A. Will the Continuing Education presentation on the new guideline for PCOS
increase the knowledge of the inflammatory correlations of obesity and PCOS?
PCOS Index with Four Dimensions
1. Elevated Tumor Necrosis Factor Alpha is an inflammatory marker that is not
associated with?
a.
b.
c.
d.
2.

Obesity
Polycystic Ovarian Syndrome
Insulin Resistance
GLP-Production

Only patients who have both Polycystic Ovarian Syndrome and obesity have
abnormalities in Tumor Necrosis Factor Alpha?
a.
b.

True
False

3. Glucose intake alters Tumor Necrosis Factor Alpha in Polycystic Ovarian
Syndrome and causes:

a.
b.
c.
d.

A decrease in insulin
An elevation in androgens
A decrease in Luteinizing Hormone (LH)
None of the above

4. An elevation in Tumor Necrosis Factor Alpha decreases the production and
increases the resistance of GLP-1 in PCOS. This correlation also occurs in obesity. This
results in:

a.
b.
c.
d.

Insulin Resistance
Weight Gain
Glucose Elevation
All the Above
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B. Will the Continuing Education presentation on the new guideline for PCOS increase
the provider’s knowledge base with diagnosing the patient with PCOS and obesity?
5. Current recommendations at the national American Diabetes Conference in 2016
involving a name change of PCOS would be?
a.
b.
c.
d.
e.

Complex Metabolic Syndrome
Metabolic Reproductive Syndrome
Reproductive Metabolic Syndrome
Androgen Reproductive Syndrome
None of the above

6.According to current practice guidelines for PCOS from the Endocrine Society,
which guidelines are recommended in diagnosing PCOS?
a.
b.
c.
d.

Rotterdam criteria
NIH criteria
AE-PCOS Society criteria
None of the above

7. According to current practice guidelines for PCOS what screening
measurements are assessed to screen for adiposity in PCOS?
a.
b.
c.
d.

BMI
Body Fat Composition
Waist Circumference
A and C

8. According to current practice guidelines what lab testing should be routinely
ordered to diagnose patients with PCOS?
a.
b.
c.
d.

TSH
Hemoglobin A1C
Lipid panel
Insulin level

C. Will the Continuing Education presentation on the new PCOS guidelines increase the
knowledge base of inflammatory co-morbidities and PCOS?
9. What is not considered a co-morbidity associated with PCOS?
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a.
b.
c.
d.
10.

Nonalcoholic fatty liver disease
Diabetes
Sleep apnea
Pancreatitis

According to the National Institute of Health, PCOS patients, with obesity
have co-morbidities that worsen their disease state. These include:
a.
b.
c.
d.

Vitamin D deficiency
Prediabetes
Hypertension
All the Above

11. Mental health conditions are a co-morbidity of PCOS?
a.
b.

True
False

12. The following is a case study regarding co-morbidities in PCOS.
“Jane Doe,” age 52 was recently released from the hospital with stage four uterine
cancer after recently having both legs amputated from Insulin Dependent Diabetes
Mellitus which is uncontrolled. She decided to not undergo any intervention for
her cancer except for her Total Abdominal Hysterectomy. She tells the doctors
and her family that she is just tired.
...”I’m sorry family, friends, and health care providers. I have attempted to find
someone since I was in high school to noticing my: missed periods, severe pelvic
pain, weight gain, excessive hair, acne, insomnia, joint pain, edema, fatigue,
episodes of rage, and low self-esteem. I ended up on lots of antidepressants and
occasional in-patient psychiatric hospitalizations. But you know, they all said it
was in my head. I was so confused because I literally ate like a bird but
continued to gain weight. No one believed me. My parents took me to many
specialists and they did say that I had Polycystic ovarian syndrome and
prescribed birth control pills. I couldn’t take them. Then I had someone
prescribe 2000 mg of Metformin a day, ’tore my stomach up. Didn’t want
anything to do with that crap.
Years went by. Someone felt sorry for me and married me. We tried for
years to have a baby; infertility drugs and all. We did in-vitro fertilization and
after $50,000.00 and three attempts I did have a baby girl. She saved my life
mentally. My focus was on her although I knew something was very wrong with
me. This time in my life was hell. I was crazy most of the time, at least I thought.
I kept gaining weight, feeling even more reclusive. I developed diabetes,
hypertension, and fatty liver disease. I was prescribed so much medicine. And
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since I hated metformin, my health care provider started me on insulin. That’s
when my life changed forever.
I kept gaining weight. I ended up with heart disease and multiple
diagnoses with more medicine. Over 300 pounds at that point, I had a heart
attack. Quadruple Bi-pass. Next, a divorce. My husband was done and told me
that my health care providers said if I would just eat right and exercise that I
would have been o.k. I was on diets and even had a gastric band. I felt so
defeated.
My daughter was having the same problems and turned 18. She went to
her local health care provider who sent her to someone who specializes in PCOS.
She was 200 pounds, no periods, and excessive hair and acne. This provider
started her on weight loss medicine, spironolactone for hyperandrogenism,
liraglutide, and a low-glycemic food plan. In one year she lost 50 pounds,
regained normal cycles, was sleeping, and developed a positive self- image.
Recently that health care provider sat down with me and cried with me
after my decision to not undergo any treatment for my cancer. She told me if I
would have been diagnosed and treated appropriately that I would probably have
been a healthy and vibrant woman at this time. I just hope the new information
on PCOS gets out so that women like me can be saved from this life imprisoned
due to a misunderstood syndrome.”
12. When reading this case study consistent symptoms and health problems being a
co-morbidity of PCOS, what appears to be the underlying issues causing this
patient to fail?
a.
b.
c.
d.

Self-Motivation
Depression
Inflammation
Health Care Providers

D. Will the Continuing Education presentation on the new PCOS Guideline increase the
provider’s knowledge of prescribing weight loss medications for the obese patient with
PCOS?
13. According to current practice guidelines in PCOS___________ is recommended
for weight loss in the PCOS patient who is overweight or obese?
a.
b.
c.
d.

Metformin
Calorie restricted diet
Phentermine
Orlistat

14. Which is not recommended in the treatment of obesity in PCOS according to the
current practice guidelines for PCOS?
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a.
b.
c.
d.

Liraglutide
Exercise
Diet Control
Reduced calories

The following are case studies. Please read the following case study and respond to the
questions based on the case.
15. "PR" is a 41-year-old female who comes to the clinic for a new patient
consultation. At today's visit, she is 5 feet 3 inches tall and 140 pounds. Her body
mass index is 25. She is not worried about her weight. She is more concerned
with no menses and hair growth on her abdomen and back. She has severe acne
that bothers her self-esteem. Only one pregnancy was induced by Clomid and
weight loss. According to the 2016 AACE/ACE clinical practice guidelines for
obesity and co-morbidity of PCOS, which in not a recommended treatment
option?
a.
b.
c.
d.

Liraglutide
Metformin
Bariatric Surgery
Phentermine

You obtain “PR” family history. Her mother and grandmother are both obese and have
been diagnosed with type 2 diabetes and hypertension. Both had a difficult time getting
pregnant. They had severe issues with their cycles and losing weight. There was no
family history of thyroid cancer or pancreatitis. Her previous history was free of those
diagnoses as well. Her lab work showed elevated fasting insulin at 23, low B12 at 145,
low Vitamin D at 17, Hgb A1c of 5.9 percent.
16. “PR” did not tolerate the Liraglutide, metformin, or orlistat. After six months
she gained 30 pounds. What is the next intervention after lifestyle and diet
according to the 2016 AACE/ACE obesity guidelines?
a.
b.
c.
d.

Phentermine
Bontril
Roux-En-Y procedure
Gastric Bi-Pass

Content Validity
Evaluating the validity of this index came from the literature review. The studies
included areas of obesity and PCOS recently published which illustrated validity of each
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test question in the instrument. This Index was developed to test the knowledge of best
practice guidelines in PCOS and obesity. Three nurse practitioners working in the area of
women’s health or family practice were planned to evaluate the instrument based on their
expertise. This was not completed due to the time frame available for presenting the
study. An evaluation survey was offered to the initial presentation participants to test the
validity of the instrument.
Procedure
The project consisted of a continuing education presentation utilizing a PowerPoint
to describe current evidence based practice guidelines and a comprehensive literature
review that related to PCOS in the obese patient. The participants were members of the 4
State APRN Group. Incentives were offered to gain voluntary participation in this
project which included a pending one hour Continuing Education credit from the
American Academy of Nurse Practitioners and a catered Italian dinner.
The continuing education presentation was delivered as the keynote presentation for
the monthly 4 State APN Group. The continuing education program was presented in
collaboration with American Academy of Nurse Practitioners, pending approval of the
research for one hour of Continuing Education. The Sullivan Clinic provided a meal for
the participants. The participants were given the pretest as they arrived for the meeting.
The presentation was viewed during the dinner. After the dinner and the presentation
was complete, the posttest was given followed by a question and answer session.
With completion of the education and posttest, an 11 question survey was given to
validate the presentation and designed instrument for this study with two being open44

ended questions. The questionnaire was based on a four point Likert scale with 4 =
strongly agree, 3 = agree, 2 = somewhat disagree, and 1 = strongly disagree. The
questions included whether the participation in the activity allowed for better
understanding of the four dimensions of the designed instrument. The second question
evaluated how knowledge was presented. The third question evaluated the
appropriateness of the presentation utilizing the design instrument. The fourth question
evaluated the cohesiveness of the content topics with the designed instrument. The fifth
question evaluated the fair and balanced coverage of the instrument. The sixth question
evaluated the disclosure of any conflict of interest. The seventh question evaluated if the
instrument was free from commercial bias. The eighth question evaluated the
recommendation to colleagues. The ninth question evaluated the enhancement of current
knowledge base with the use of the instrument.
After the confidential evaluation was completed by the 18 participants, the forms
were placed in an envelope and secured in a safe at the Sullivan clinic. At a separate time,
the 18 evaluations were tallied having 9 Likert scale questions. Scores were tallied.
After totals of each questions were figured, Cronbach’s Alpha was utilized to evaluate
internal validity.
Data Collection and Measurement
This research consisted as a sample of convenience based on the quasi-experimental
design for an index correlating four dimensions from the literature review. (Babbie,
2014). The population for this capstone project included nurse practitioners and nurse
practitioner students from Kansas, Missouri, Oklahoma and Arkansas who attended the $
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State APN Group’s monthly meeting in October, 2016. The meeting was held at The
Sullivan Clinic in Frontenac, KS. The 4-State APN is an area group of professionals that
meet monthly. It was voluntary and no monetary compensation was offered to complete
the webinar.
The pretest was secured in a confidential manner during the presentation. All data
were kept confidential and all participants were kept anonymous. To measure the
dependent variable, the correct response was valued as a one. The incorrect response was
valued as zero. The total scores were tallied. The totals were divided by the number of
correct answers to give a mean value. The highest total value was 16 with the lowest
value being zero. There were four dimensions which had four questions each. Each
dimension was tallied from a zero to four to evaluate the number of questions correct.
These values were converted and presented as a percentage. Separating the total correct
answers divided into four dimensions allowed for feedback analysis in the validity of the
presentation and instrument.
Statistical analysis was performed utilizing Excel in spreadsheet format.
Statistical significance allowed for a probability level acceptable as p<0.05. A paired ttest was conducted on the pretest and posttest results; one = yes, zero = no. Evaluation
measures assessed within the parameters of each dimension of the overall project.
Quantitative analysis used descriptive statistics and standard deviation to identify whether
pre-test evaluations were statistically significant in comparison with post-test data. The
correlation between different variables were determined again using P value <0.05 as an
ANOVA/Spearman.
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Evaluation Measures Linked to Objectives
Evaluation measures were linked to the objectives utilizing the logic model
(Figure 2). This project measured the participants’ knowledge of the diagnosis and
treatment of obese PCOS patients with updated treatment guidelines before and after an
educational program. The measured outcomes being evaluated were diagnostic criteria,
diagnosis, pathophysiology, and treatment. A positive outcome was indicated by an
increase in percentage of correct answers posttest. The long term goal of this research
was to increase the awareness and knowledge of the diagnosis and treatment of the PCOS
patient with obesity. Due to time this was not able to be measured with this research.
The research instrument was in a pretest and posttest format. The dependent
variable consisted of 16 questions. A survey tool was established specific for this
research since it involved a paradigm shift in the diagnosis and treatment of PCOS in
obesity. It included multiple styles of questions including true and false, multiple choice,
and case studies. An over-all score was utilized for the results. Table 7 describes the
projected results of this research project.
Table 7. Objectives, Measurements and Outcomes
Objective
Participants will
identify correctly
the inflammatory
correlations of
obesity and PCOS.

The continuing
education
presentation will

Measurement
Participants will
have an increase in
correct responses
regarding
inflammatory
correlations between
obesity and PCOS
Participants increase
correct answers
concerning the

Outcome

Analysis

Participants will
choose the correct
inflammatory
correlations in the
obesity and PCOS.

Paired t-test
pretest/posttest
format.

Participants will
appropriately
identify the correct

Paired t-test
pretest/posttest
format.
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increase the
provider’s ability in
diagnosing the
patient with PCOS
and obesity?

diagnosis of patients
with PCOS and
obesity.

diagnosis of patients
with PCOS and
obesity.

The continuing
education
presentation will
increase the
knowledge of
inflammatory comorbidities with
obesity and PCOS?

Participants increase
correct answers
concerning the
increase the
knowledge of
inflammatory comorbidities with
obesity and PCOS.

Participants will
recognize the
inflammatory comorbidities with
PCOS and obesity.

Paired t-test
pretest/posttest
format.

The continuing
education
presentation will
increase the
provider’s
knowledge in
prescribing weightloss medications for
the obese patient
with PCOS?

Participants will
have an increase in
correct responses to
questions regarding
the treatment the
obese patient with
PCOS with weight
loss medications

Participants will
learn the correct
treatment of the
obese patient with
PCOS with weight
loss medications.

Paired t-test
pretest/posttest
format.

Conclusion
With PCOS occurring in over 5 million women of childbearing age, continuous
therapies and understanding of the cause is imperative. This researcher has witnessed
hundreds of case studies personally with both positive and negative outcomes because of
the lack of FDA approved therapies for treatment as well as a misunderstanding of the
disease process alone.
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GLP-1 agonists have been shown in small studies across the world to decrease
weight and inflammation in these affected women. Hopefully through persistence and
education, this research is part of the revolution of treatments and further research for this
continued complex disease which has imprisoned the quality of life of millions of women
thus far.
This project consisted of an educational program, the design of a pretest and
posttest instrument in the form of an index, and validation of the instrument in the form
of a 4 point Likert scale. Chapter IV discusses the results of the study.
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CHAPTER IV

FINDINGS

Introduction
The findings in this scholarly project were analyzed to determine if an increase in
knowledge emerged. The potential increase in the knowledge acquired regarding PCOS
practice guidelines following a continuing education presentation on new guidelines for
obese, PCOS patients. A group of nurse practitioners and nurse practitioner students
listened to the presentation and observed a PowerPoint presentation after a pretest over
the contents of the presentation. A posttest was completed after the presentation was
given. The sample included 18 total participants at this evening event. The data were
analyzed providing quantitative data. The survey provided information on the
educational offering and the posttest validated whether an increase in knowledge level of
PCOS practice guidelines was observed. Following the collection of demographic data,
the pretest data were collected regarding current guideline information and the
pathophysiology of inflammation and PCOS. After the presentation, the same test was
given to the subjects. The pretest and posttest contained sixteen questions separated into
four distinct domains:
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1. Will the Continuing Education presentation on the new PCOS Guideline
increase the knowledge base of the correlations between obesity and PCOS?
2. Will the Continuing Education presentation on the new PCOS Guideline
increase the knowledge base of diagnosing the patient with PCOS and
obesity?
3. Will the Continuing Education presentation on the new PCOS Guideline
increase the knowledge base of inflammatory co-morbidities and PCOS?
4. Will the Continuing Education presentation on the new PCOS Guideline
increase the provider’s knowledge of prescribing weight loss medications for
the obese patient with PCOS?
Demographic Data
The demographic data gathered from the participants included practice setting and
years of experience and is Presented in Table 5. Thirty-three percent (N=6) of
practitioners were employed in a Family Practice setting. Nurse practitioners employed
in Women’s Health included one participant (N=1 or six percent). Six percent (n=1)
were employed in the Emergency Department. The student participants consisted of 17
percent (n=3) of the subjects. Nurse Educators represented 22 percent (n=3). There was
one Cardiothoracic Nurse Practitioner in the group of subjects which represented six
percent of the population. Wound Care nurse practitioners represented eleven percent of
the population (n=2).
The total years as a nurse practitioner was calculated from 0-3 years, 3-5 years, 510 years, and 10-20 years. Thirty-three percent represented 0-3 years of clinical
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experience as a nurse practitioner. Six percent represented 3-5 years. Thirty-three
percent represented 5-10 years and twenty-eight percent represented 10-20 years.
In a yes or no question, each participant was asked if they were currently taking
care of patients with PCOS. The responses revealed that 28 percent of the subjects were
currently taking care of patients with PCOS.
Table 8. Demographic Information of Attendance at Presentation

Participatns

Demographics

18
16
14
12
10
8
6
4
2
0

Pretest and Posttest
All of the subjects participating in the project were given a pretest prior to the
presentation and a posttest followed. The testing was grouped according the name on the
test giving permission to use the results in this project. Each test was identical in each of
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the 16 questions. These questions were divided into four domains to make up an index.
The first domain included questions on the inflammatory correlations of obesity and
PCOS. The second domain included questions on the diagnosis of a patient with obesity
and PCOS. The third domain included questions on the inflammatory co-morbidities and
PCOS. The fourth domain included questions regarding the new guidelines in
prescribing weight loss medication to the obese female with a co-morbidity of PCOS.
Results
Quantitative data. Each Dimension was tallied separately with 4 possible correct
answers within each of the four categories. The mean pretest score for Dimension one
was 3.0556 with a standard deviation of 0.9376 in the pretest group. The mean posttest
score for Dimension one was 3.4444 with a standard deviation of 0.70479. The
differences in the pretest score and the posttest score had a mean of -0.3889
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Table 9. Dimension One Pretest/Posttest Scores

with a standard deviation of 1.33456. The difference in test scores was not found to be
statistically significant although most respondents had an increase in posttest scores as
evidenced in Table 9.
The mean pretest score for Dimension two was 2.2222 with a standard deviation of
0.54832 in the pretest group. The mean posttest score for Dimension one was 3.1667
with a standard deviation of 0.87549. The differences in the pretest score and the posttest
score had a median of -0.9444 with a standard deviation of 0.93769. Statistical
significance was found at p<0.001. The majority of respondents had an increase in
posttest scores as evidenced in Table 10.
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Table 10. Dimension Two pretest and posttest results

The mean pretest score for Dimension three was 2.2222 with a standard deviation
of 0.8782 in the pretest group. The mean posttest score for Dimension one was 2.3333
with a standard deviation of 0.76696. The differences in the pretest score and the posttest
score had a mean of -0.1111 with a standard deviation of 1.02262. Statistical significance
was not found with a p> 0.05. Some respondents had a decrease in posttest scores as
evidenced in table 11.
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Table 11. Dimension Three Pretest/Posttest Scores

The mean pretest score for Dimension four was 0.7778 with a standard deviation
of 0.80845 in the pretest group. The mean posttest score for Dimension one was 3.3333
with a standard deviation of 0.84017. The differences in the pretest score and the posttest
score had a mean of -2.5556 with a standard deviation of 1.09664. All respondents had
an increase in posttest scores as evidenced in table 12. Statistical Significance was found
in this dimension at p<0.
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Table 12. Dimension four Pretest/Posttest Scores

Validity of the index. Due to time constraints of the acceptance date of the
proposal and the change of dates in the project presentation, validity of the index was
tested at this presentation with all 18 subjects completing the 4 point Likert scale
questionnaire with a place for open ended suggested changes. Nine questions were
asked. There were no open ended suggestions noted. Cronbachs’ Alpha was utilized to
test the internal validity of the
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Table 13. Paired t-test sampling revealing paired differences

Paired Samples Test
Paired Differences
95% Confidence Interval
of the Difference
Mean

Std. Deviation

Std. Mean Error Lower

Upper

t

df

Sig. (2-tailed

Pair 1 Pretest-Posttest

-0.3889

1.33456

0.31456 -1.0526 0.27477 -1.236

17

0.233

Pair 2 Pretest-Posttest

-0.9444

0.93769

0.22099 -1.4107 -0.47819 -4.274

17

0.001

Pair 3 Pretest-Posttest

-0.1111

1.02262

0.24103 -0.6197 0.39743 -0.461

17

0.651

Pair 4 Pretest-Posttest

-2.5556

1.09664

0.25848 -3.1009 -2.01021 -9.887

17

0

pretest, posttest and survey. The pretest results were 0.974532. The posttest results were
0.418406285. The 4 point Likert scale survey results were 0.658537. According to these
results, the posttest did not score well according to Cronbachs’ Alpha. Better
presentation of the information should be considered in the future.
Chapter Summary
Chapter four delineated the statistical analysis of the pretest and posttest of the
capstone project. Overall, the learning objectives did show an increase in knowledge
from the pretest to the posttest results. Each of the four research questions focused on the
diagnosis, co-morbidity, and treatment of the obese, PCOS patient. The quantitative data
gathered displayed an increase in the posttest scores with two out of the four dimensions
showing a statistical significance with a p value at <0.000001. The findings of the study
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did support the title being a paradigm shift in the diagnosis and treatment of PCOS.
Continued education on recently updated guidelines in PCOS and obesity is warranted to
continue dissemination of this knowledge in nursing. Chapter V discusses the future
recommendations for research along with limitations of the project and conclusions.
Table 14. PCOS Descriptive Statistics
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CHAPTER V

CONCLUSIONS

Introduction
This project provided nurse practitioners and nurse practitioner students the
opportunity to receive an education offering on the recently released practice guidelines
on obesity and the PCOS patient. The continuing education offering was designed
utilizing an instrument to test knowledge gained in a pretest and posttest fashion. The
research design allowed the ability to conclude whether a statistically significant analysis
was positive after the presentation to increase the knowledge in this subject area. The
study focused on these four research questions:
1. Will the Continuing Education presentation on the new PCOS Guideline
increase the knowledge base of the correlations between obesity and PCOS?
2. Will the Continuing Education presentation on the new PCOS Guideline
increase the knowledge base of diagnosing the patient with PCOS and
obesity?
3. Will the Continuing Education presentation on the new PCOS Guideline
increase the knowledge base of inflammatory co-morbidities and PCOS?
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4. Will the Continuing Education presentation on the new PCOS Guideline
increase the provider’s knowledge of prescribing weight loss medications for
the obese patient with PCOS?
The nurse practitioner continuing education program was presented to a local
group of nurse practitioners and nurse practitioner students. A pretest and posttest was
completed prior to and immediately following the educational offering.
Limitations
The limitation of this project was the paradigm shift in how PCOS is diagnosed
and treated in the obese population. It was difficult to attempt to present this information
on the inflammatory connections between PCOS and obesity rather than just focusing on
the gynecological aspect of PCOS. A second limitation involved having the information
and results from a sample of convenience and would a different population setting
produce similar results? All participants were female (n=18). A third limitation was the
design of the instrument for this project. Due to limited time in the presentation and
utilization of the instrument, the validity was not able to be completed prior to the
educational PowerPoint presentation. This presentation was utilized for validation of the
tool using a 4 point Likert scale survey. These questions were developed by the primary
investigator and not standardized. All efforts were taken to validate the instrument for
future educational opportunities.
Two out of four dimensions of the pretest and posttest comparison were found to
be statistically significant. There needs to be better assimilation of education from the
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PowerPoint for an increase in gained knowledge from the PowerPoint to increase
statistical significance of test scores in all four dimensions.
Future Research
Due to the updated practice guidelines for PCOS and obesity, this project allows
for a change in the approach to treating PCOS. Research validates the need for education
at the provider level in the pathophysiology of PCOS. Even after the PowerPoint
presentation, some questions continued to be answered incorrectly.
In May, 2016, it was suggested that PCOS should have a name change of the
condition to Metabolic Reproductive Disorder. With representing a metabolic connection
to the disease state, Nursing can begin to support this concept by educating and
collaborating with other health care professions to assist in the positive outcomes in these
women.
Sustainability
The sustainability of this research involves the continued search for opportunities
to disseminate the information in this capstone project. With PCOS being the number
one endocrine disorder in women, it is of great need for this approach with PCOS be
supported. Opportunities for educating the public and healthcare professionals will be
pursued. Television programs along with journal articles will be pursued.
Dissemination of Information
This project along with the statistical analysis of the increased knowledge in
PCOS did find the need for more knowledge on this research in healthcare and the
general public. For the medical community, updated guidelines in PCOS and obesity will
need to be taught in schools and continuing education programs. For the public, allowing
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a simple explanation of this research is needed to better understand the knowledge at a
basic level. Acceptance of this change in the approach to PCOS is important across the
board.
This PowerPoint presentation is pending approval for one Continuing Education
credit through American Academy of Nurse Practitioners organization. This Continuing
Education program has the potential to disseminate this knowledge across all forms of
education pathways. Another potential idea for dissemination of information would
include a policy brief for state and national legislatures which would allow for
government backing in funding opportunities and government support.
Chapter Summary
This DNP Scholarly Project allowed for the participants to be given an
opportunity to enjoy an Italian dinner along with a continuing education presentation
regarding the updated guidelines for PCOS and obesity. In addition, the continuing
education program provide education regarding the inflammatory connections of PCOS
and obesity. Studies and current trends in PCOS reveal that updated education of current
knowledge is lacking. The research also reveals the misleading name as it relates to an
ovarian problem rather than a metabolic, inflammatory etiology. The research provided
in this capstone project is vital to linking inflammation to PCOS and obesity in how the
treatment of this disorder will be approached in the future. The co-morbidities of PCOS
and obesity have the potential to increase the risk of multiple inflammatory disease such
as diabetes, heart disease, and cancer. Primary care providers must be given the
opportunity to continue understanding the paradigm shift in the diagnosis and treatment
of obesity in the PCOS patient.
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APPENDIX

APPENDIX A
A Paradigm Shift in the Diagnosis and Treatment of Polycystic Ovarian Syndrome:
A Practice Change Index
Four Dimensions
I, ______________________, authorize my consent to complete the pre/posttest in order
to identify areas of improvement for this presentation. Recommendations will be written
on the posttest.
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APPENDIX B
PRETEST/POSTTEST
PCOS Index with Four Dimensions

A. Will the Continuing Education presentation on the new guideline for PCOS
increase the knowledge of the inflammatory correlations of obesity and
PCOS?
1. Elevated Tumor Necrosis Factor Alpha is an inflammatory marker that is not
associated with?
a. Obesity
b. Polycystic Ovarian Syndrome
c. Insulin Resistance
d. Increased GLP-Production
2. Only patients who have both Polycystic Ovarian Syndrome and obesity have
abnormalities in Tumor Necrosis Factor Alpha?
a. True
b. False
3. Glucose intake alters Tumor Necrosis Factor Alpha in Polycystic Ovarian
Syndrome and causes:
a. A decrease in insulin
b. An elevation in androgens
c. A decrease in Luteinizing Hormone (LH)
d. None of the above
4. An elevation in Tumor Necrosis Factor Alpha decreases the production and
increases the resistance of GLP-1 in PCOS. This correlation also occurs in
obesity. This results in:
a. Insulin Resistance
b. Weight Gain
c. Glucose Elevation
d. All the Above

B. Will the Continuing Education presentation on the new guideline for PCOS
increase the provider’s knowledge base with diagnosing the patient with
PCOS and obesity?
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5. Current recommendations at the national American Diabetes Conference in 2016
involving a name change of PCOS would be?
a. Complex Metabolic Syndrome
b. Metabolic Reproductive Syndrome
c. Reproductive Metabolic Syndrome
d. Androgen Reproductive Syndrome
e. None of the above

6. According to current practice guidelines for PCOS from the Endocrine Society,
which guideline is recommended in diagnosing PCOS?
a. Rotterdam criteria
b. NIH criteria
c. AE-PCOS Society criteria
d. None of the above
7. According to current practice guidelines for PCOS what screening measurements
are assessed to screen for adiposity in PCOS?
a. BMI
b. Body Fat Composition
c. Waist Circumference
d. A and C
8. According to current practice guidelines what lab testing should be routinely
ordered to diagnose patients with PCOS?
a. Free Testosterone
b. Uric Acid
c. ESR
d. CBC
C. Will the Continuing Education presentation on the new PCOS guidelines
increase the knowledge base of inflammatory co-morbidities and PCOS?
9. What is not considered a co-morbidity associated with PCOS?
a. Nonalcoholic fatty liver disease
b. Diabetes
c. Sleep apnea
d. Pancreatitis
10. According to the National Institute of Health, PCOS patients, with obesity have
co-morbidities that worsen their disease state. These include:
a. Insulin Resistance
b. Prediabetes
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c. Hypertension
d. All the Above
11. Mental health conditions are a co-morbidity of PCOS?
a. True
b. False
The following is a case study regarding co-morbidities in PCOS.
“Jane Doe,” age 52 was recently released from the hospital with stage four uterine cancer
after recently having both legs amputated from Insulin Dependent Diabetes Mellitus
which is uncontrolled. She decided to not undergo any intervention for her cancer except
for her Total Abdominal Hysterectomy. She tells the doctors and her family that she is
just tired.
“I’m sorry family, friends, and health care providers. I have attempted to find someone
since I was in high school to noticing my: missed periods, severe pelvic pain, weight
gain, excessive hair, acne, insomnia, joint pain, edema, fatigue, episodes of rage, and low
self-esteem. I ended up on lots of antidepressants and occasional in-patient psychiatric
hospitalizations. But you know, they all said it was in my head. I was so confused
because I literally ate like a bird but continued to gain weight. No one believed me. My
parents took me to many specialists and they did say that I had Polycystic ovarian
syndrome.
Years went by and I married and tried for years to have a baby. I even attempted
infertility drugs and that didn’t work. We did in-vitro fertilization and after $50,000.00 I
did have a girl. I knew something was very wrong with me. This time in my life was
hell. I was crazy most of the time. I kept gaining weight, feeling even more reclusive. I
developed diabetes, hypertension, and fatty liver disease. I was prescribed so much
medicine. And since I hated metformin, my health care provider started me on insulin.
That is what fueled my downward slide.
I kept gaining weight. Over 300 pounds at that point, I had a heart attack. Quadruple
Bi-pass. Next, a divorce. My husband was done and told me that my health care
providers said if I would just eat right and exercise that I would have been o.k. I was on
diets, ran 5ks, ate 500 calories, drank lemon/vinegar water, and even a gastric band. I felt
so defeated.
My daughter was having the same problems and turned 18. She went to her local health
care provider who sent her to someone who specializes in PCOS. She was 200 pounds,
no periods, and excessive hair and acne. This provider started her on weight loss
medicine, spironolactone for hyper-androgenism, liraglutide, and a low-glycemic food
plan. In one year she lost 50 pounds, regained normal cycles, was sleeping, and
developed a positive self- image.
Recently that health care provider sat down with me and cried with me after my decision
to not undergo any treatment for my cancer. She told me if I would have been diagnosed
and treated appropriately that I would probably have been a healthy and vibrant woman at
this juncture instead of hospice.”
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12. When reading this case study, consistent symptoms and health problems being a
co-morbidity of PCOS, what appears to be the underlying issues that caused
this patient to fail?
a. Self-Motivation
b. Depression
c. Inflammation
d. Health Care Providers
D. Will the Continuing Education presentation on the new PCOS Guideline
increase the provider’s knowledge of prescribing weight loss medications for
the obese patient with PCOS?
13. According to current 2013 Endocrine Society practice guidelines in
PCOS___________ is recommended for weight loss in the PCOS patient who is
overweight or obese?
a. Metformin
b. Calorie restricted diet
c. Phentermine
d. Orlistat
14. Which is not recommended in the treatment of obesity in PCOS according to the
current 2013 Endocrine Society practice guidelines for PCOS?
a. Liraglutide
b. Exercise
c. Diet control
d. Reduced calories
15. "PR" is a 41-year-old female who comes to the clinic for a new patient
consultation. At today's visit, she is 5 feet 3 inches tall and 140 pounds. Her body
mass index is 25. She is not worried about her weight. She is more concerned
with no menses and hair growth on her abdomen and back. She has severe acne
that bothers her self-esteem. Only one pregnancy was induced by Clomid and
weight loss. According to the 2016 AACE/ACE clinical practice guidelines for
obesity and co-morbidity of PCOS, which in not a recommended treatment
option?
a. Liraglutide
b. Metformin
c. Bariatric Surgery
d. Phentermine
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16. You obtain “PR’s” family history. Her mother and grandmother are both obese
and have been diagnosed with type 2 diabetes and hypertension. Both had a
difficult time getting pregnant. They had severe issues with their cycles and
losing weight. There was no family history of thyroid cancer or pancreatitis. Her
previous history was free of those diagnoses as well. Her lab work showed
elevated fasting insulin at 23, low B12 at 145, low Vitamin D at 17, HgbA1c of
5.9%. “PR” did not tolerate the Liraglutide, metformin, or orlistat. After six
months, she gained 30 pounds. What is the next intervention after lifestyle and
diet according to the 2016 AACE/ACE obesity guidelines?
a. Phentermine
b. Bontrix
c. Roux-en-Y Gastric Bi-Pass
d. Tradjenta
Thank you for completing the pre/posttest!
Recommendations for future presentations:
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